NA Viscosupplementation Market - Industry Trends and Forecast to 2029
- Published Date: 2022-12-22
- Report ID: 143344
- Pages: 225
-
Format:
Short Description
North America Viscosupplementation Market, By Source (animal origin and non-animal origin), Age Group (geriatric and adults), Injection (single injection, three injections, and five injections), Molecular Weight (intermediate molecular weight, low molecular weight, and high molecular weight), End User (hospital, orthopedic clinics, ambulatory care centers, and others), Distribution Channel (direct tender and retail sales), Country(U.S., Canada, Mexico, Panama, Jamaica, and the Dominican Republic) Industry Trends and Forecast to 2029.
Market Definition:
The development of the therapeutic paradigm viscosupplementation for long-lasting pain relief in human and animal joints with osteoarthritis or traumatic arthritis was based on the finding that in arthritic conditions, the average molecular weight and concentration of hyaluronan decreased. Consequently, the elastoviscous properties of the synovial fluid are substantially reduced. Viscosupplementation is a therapeutic process in which the pathological synovial fluid or effusion is removed from the joint by arthrocentesis and is replaced with a highly purified hyaluronan solution which has a 16- to 30-times greater concentration than the pathological joint fluid, and a 2- to 5-times greater concentration than that of the hyaluronan in the healthy synovial fluid. In some preparations of hyaluronan used today for therapeutic purposes, the rheological properties (viscosity and elasticity) are low. Therefore the elastoviscosity of the fluid is similar to that of fluid removed from an arthritic joint. Another preparation available to patients worldwide is composed of hyaluronan derivatives (hylans) with substantially greater elastoviscosity than hyaluronan solutions. It has comparable rheological properties to those of the fluid found in young, healthy individuals. The clinical benefit of viscosupplementation is long-lasting pain relief in arthritic joints.
Furthermore, the increasing demand for non-surgical treatments for osteoarthritis, the prevalence of lifestyle-induced disorders, and advancements in the development of hyaluronic acid-based therapies are some of the factors expected to drive the market.
Market Segmentation:
North America viscosupplementation market is categorized into six notable segments, which are source, age group, molecular weight, injection, end user, and distribution channel.
On the basis of source, the global viscosupplementation market is segmented into the animal origin and non-animal origin. Animal origin is further segmented into by type, hyaluronans, by brands, hylan G-F 20, by brand, Synvisc, and Synvisc one. Hyaluronans, by brands, are further segmented into hyalgan. Non-animal origin is segmented into SULPLASYN, GEL ONE, ORTHOVISC, MONOVISC, OSTEONIL, VISCOSEAL, EUFLEXXA, DUROLANE, SUPARTZ, GELSYN-3, and CINGEAL. In 2022, the non-animal origin segment is expected to dominate the global viscosupplementation market due to the increased density of hyaluronic acid (HA). Also, it displays high resistance to intraarticular degradation
On the basis of age group, the global viscosupplementation market is segmented into geriatric and adults. In 2022, the geriatric segment is expected to dominate the global viscosupplementation market due to an increase in the population
On the basis of injection, the global viscosupplementation market is segmented into single injections, three injections, and five injections. In 2022, the single injection segment is expected to dominate the global viscosupplementation market due to high responsiveness levels to single-injection treatment and a more prominent inclination for the administration of osteoarthritis
On the basis of molecular weight, the global viscosupplementation market is segmented into intermediate molecular weight, low molecular weight, and high molecular weight. In 2022, the intermediate molecular weight segment is expected to dominate the global viscosupplementation market due to the molecular weight of hyaluronic acid having a major influence on its efficacy and safety for viscosupplementation in hip osteoarthritis
On the basis of end-user, the global viscosupplementation market is segmented into hospitals, orthopedic clinics, ambulatory care centers, and others. In 2022, the hospital segment is expected to dominate the global viscosupplementation market due to rising preferences among customers
On the basis of distribution channel, the global viscosupplementation market is segmented into direct tender and retail sales. In 2022, the direct tender segment is expected to dominate the global viscosupplementation market as it is most commonly used by research labs, pharmaceutical shops, and hospitals
Market Players
The key market players operating in the North America viscosupplementation market are listed below:
SA
Ortobrand International
TRB CHEMEDICA SA
Teva Pharmaceutical Industries Ltd.
Lifecore (a subsidiary of Landec Corporation)
VIRCHOW BIOTECH
Zuventus HealthCare Ltd. (a subsidiary of Emcure Pharmaceuticals)
TABLE OF CONTENTS
1 INTRODUCTION 59
1.1 OBJECTIVES OF THE STUDY 59
1.2 MARKET DEFINITION 59
1.3 OVERVIEW OF NORTH AMERICA VISCOSUPPLEMENTATION MARKET 59
1.4 CURRENCY AND PRICING 61
1.5 LIMITATIONS 61
1.6 MARKETS COVERED 62
2 MARKET SEGMENTATION 65
2.1 MARKETS COVERED 65
2.2 GEOGRAPHICAL SCOPE 66
2.3 YEARS CONSIDERED FOR THE STUDY 67
2.4 DBMR TRIPOD DATA VALIDATION MODEL 68
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 71
2.6 MULTIVARIATE MODELLING 72
2.7 MARKET APPLICATION COVERAGE GRID 73
2.8 SOURCE LIFELINE CURVE 74
2.9 DBMR MARKET POSITION GRID 75
2.10 VENDOR SHARE ANALYSIS 76
2.11 SECONDARY SOURCES 77
2.12 ASSUMPTIONS 77
3 EXECUTIVE SUMMARY 78
4 PREMIUM INSIGHT 82
4.1 PESTEL 83
4.2 PORTER'S FIVE FORCES MODEL 84
5 EPIDEMIOLOGY 85
6 INDUSTRIAL INSIGHTS 86
7 PIPELINE ANALYSIS FOR NORTH AMERICA VISCOSUPPLEMENTATION MARKET 88
8 NORTH AMERICA VISCOSUPPLEMENTATION MARKET: REGULATIONS 89
9 MARKET OVERVIEW 92
9.1 DRIVERS 94
9.1.1 RISING GERIATRIC POPULATION 94
9.1.2 INCREASING RISK OF OSTEOPOROSIS AND OSTEOARTHRITIS 94
9.1.3 TECHNOLOGICAL ADVANCEMENT IN VISCOSUPPLEMENTATION 95
9.1.4 LOW PRODUCTION COST OF VISCOSUPPLEMENTATION PRODUCTS 95
9.2 RESTRAINTS 95
9.2.1 LACK OF TECHNICAL EXPERTISE 95
9.2.2 PRODUCT RECALL PROCEDURES 96
9.2.3 LIMITED APPLICATIONS OF VISCOSUPPLEMENTATION 96
9.3 OPPORTUNITIES 96
9.3.1 SAFETY AND EFFECTIVENESS OF INTRA-ARTICULAR HYALURONIC ACID (IAHA) 96
9.3.2 RISING HEALTHCARE INFRASTRUCTURE 97
9.3.3 INCREASE IN DEMAND FOR MINIMALLY INVASIVE PROCEDURES 97
9.3.4 INCREASING NUMBER OF JOINT REPLACEMENTS AND SPORTS ACCIDENT 98
9.4 CHALLENGES 98
9.4.1 STRINGENT GOVERNMENT POLICIES FOR THE USE OF VISCOSUPPLEMENTATION 98
9.4.2 SIDE-EFFECTS OF VISCOSUPPLEMENTATION 99
10 NORTH AMERICA VISCOSUPPLEMENTATION MARKET, BY SOURCE 100
10.1 OVERVIEW 101
10.2 NON-ANIMAL ORIGIN 103
10.2.1 ORTHOVISC 105
10.2.2 EUFLEXXA 105
10.2.3 MONOVISC 105
10.2.4 DUROLANE 105
10.2.5 GEL-ONE 106
10.2.6 SUPARTZ 106
10.2.7 GELSYN-3 106
10.2.8 CINGAL 106
10.2.9 SULPLASYN 106
10.2.10 VISCOSEAL 106
10.2.11 OSTEONIL 106
10.2.12 OTHERS 106
10.3 ANIMAL ORIGIN 106
10.3.1 HYLAN G-F 20 107
10.3.2 SYNVIC ONE 108
10.3.3 SYNVIC 108
10.3.4 OTHERS 108
10.3.5 HYALURONANS 108
10.3.6 HYALGAN 109
10.3.7 OTHERS 109
11 NORTH AMERICA VISCOSUPPLEMENTATION MARKET, BY MOLECULAR WEIGHT 110
11.1 OVERVIEW 111
11.2 INTERMEDIATE MOLECULAR WEIGHT 113
11.2.1 ORTHOVISC 114
11.2.2 EUFLEXXA 114
11.2.3 MONOVISC 115
11.2.4 DUROLANE 115
11.2.5 VISCOSEAL 115
11.2.6 OSTEONIL 115
11.2.7 OTHERS 115
11.3 LOW MOLECULAR WEIGHT 115
11.3.1 HYLAGAN 116
11.3.2 SUPARTZ 116
11.3.3 GELSYN-3 116
11.3.4 CINGAL 116
11.3.5 SULPLASYN 117
11.3.6 OTHERS 117
11.4 HIGH MOLECULAR WEIGHT 117
11.4.1 SYNVIC ONE 118
11.4.2 SYNVIC 118
11.4.3 OTHERS 118
12 NORTH AMERICA VISCOSUPPLEMENTATION MARKET, BY INJECTION 119
12.1 OVERVIEW 120
12.2 SINGLE INJECTION 122
12.3 THREE INJECTION 123
12.4 FIVE INJECTION 124
13 NORTH AMERICA VISCOSUPPLEMENTATION MARKET, BY AGE GROUP 125
13.1 OVERVIEW 126
13.2 ADULTS 128
13.3 GERIATRIC 129
14 NORTH AMERICA VISCOSUPPLEMENTATION MARKET, BY END USER 130
14.1 OVERVIEW 131
14.2 HOSPITALS 133
14.3 ORTHOPEDIC CLINICS 134
14.4 AMBULATORY CARE CENTERS 135
14.5 OTHERS 136
15 NORTH AMERICA VISCOSUPPLEMENTATION MARKET, BY DISTRIBUTION CHANNEL 137
15.1 OVERVIEW 138
15.2 RETAIL SALES 140
15.3 DIRECT TENDER 141
16 NORTH AMERICA VISCOSUPPLEMENTATION MARKET, BY REGION 142
16.1 NORTH AMERICA 143
16.1.1 U.S. 152
16.1.2 CANADA 157
16.1.3 MEXICO 162
16.1.4 PANAMA 167
16.1.5 JAMAICA 172
16.1.6 DOMINICAN REPUBLIC 176
17 NORTH AMERICA VISCOSUPPLEMENTATION MARKET: COMPANY LANDSCAPE 180
17.1 COMPANY SHARE ANALYSIS: NORTH AMERICA 180
18 SWOT ANALYSIS 181
19 COMPANY PROFILE 182
19.1 JOHNSON & JOHNSON SERVICES, INC. 182
19.1.1 COMPANY SNAPSHOT 182
19.1.2 REVENUE ANALYSIS 182
19.1.3 COMPANY SHARE ANALYSIS 183
19.1.4 PRODUCT PORTFOLIO 183
19.1.5 RECENT DEVELOPMENTS 183
19.2 BIOVENTUS 184
19.2.1 COMPANY SNAPSHOT 184
19.2.2 REVENUE ANALYSIS 184
19.2.3 COMPANY SHARE ANALYSIS 185
19.2.4 PRODUCT PORTFOLIO 185
19.2.5 RECENT DEVELOPMENTS 186
19.3 FERRING B.V. 187
19.3.1 COMPANY SNAPSHOT 187
19.3.2 COMPANY SHARE ANALYSIS 187
19.3.3 PRODUCT PORTFOLIO 187
19.3.4 RECENT DEVELOPMENT 187
19.4 SANOFI-AVENTIS U.S. LLC 188
19.4.1 COMPANY SNAPSHOT 188
19.4.2 REVENUE ANALYSIS 188
19.4.3 COMPANY SHARE ANALYSIS 189
19.4.4 PRODUCT PORTFOLIO 189
19.4.5 RECENT DEVELOPMENTS 189
19.5 ZIMMER BIOMET 190
19.5.1 COMPANY SNAPSHOT 190
19.5.2 REVENUE ANALYSIS 190
19.5.3 COMPANY SHARE ANALYSIS 191
19.5.4 PRODUCT PORTFOLIO 191
19.5.5 RECENT DEVELOPMENTS 192
19.6 SEIKAGAKU CORPORATION 193
19.6.1 COMPANY SNAPSHOT 193
19.6.2 REVENUE ANALYSIS 193
19.6.3 PRODUCT PORTFOLIO 194
19.6.4 RECENT DEVELOPMENTS 194
19.7 ANIKA THERAPEUTICS, INC. 195
19.7.1 COMPANY SNAPSHOT 195
19.7.2 REVENUE ANALYSIS 195
19.7.3 PRODUCT PORTFOLIO 196
19.7.4 RECENT DEVELOPMENTS 196
19.8 FIDIA FARMACEUTICI S.P.A 197
19.8.1 COMPANY SNAPSHOT 197
19.8.2 REVENUE ANALYSIS 197
19.8.3 PRODUCT PORTFOLIO 197
19.8.4 RECENT DEVELOPMENT 198
19.9 APTISSEN 199
19.9.1 COMPANY SNAPSHOT 199
19.9.2 PRODUCT PORTFOLIO 199
19.9.3 RECENT DEVELOPMENT 199
19.10 IBSA INSTITUT BIOCHIMIQUE SA 200
19.10.1 COMPANY SNAPSHOT 200
19.10.2 PRODUCT PORTFOLIO 200
19.10.3 RECENT DEVELOPMENT 200
19.11 LG CHEM. 201
19.11.1 COMPANY SNAPSHOT 201
19.11.2 REVENUE ANALYSIS 201
19.11.3 PRODUCT PORTFOLIO 202
19.11.4 RECENT DEVELOPMENTS 202
19.12 LIFECORE (A SUBSIDIARY OF LANDEC CORPORATION) 203
19.12.1 COMPANY SNAPSHOT 203
19.12.2 REVENUE ANALYSIS 203
19.12.3 PRODUCT PORTFOLIO 204
19.12.4 RECENT DEVELOPMENTS 204
19.13 ORTHOGENRX, INC. (A SUBSIDIARY OF AVNS) 205
19.13.1 COMPANY SNAPSHOT 205
19.13.2 REVENUE ANALYSIS 205
19.13.3 PRODUCT PORTFOLIO 205
19.13.4 RECENT DEVELOPMENTS 206
19.14 ORTOBRAND INTERNATIONAL 207
19.14.1 COMPANY SNAPSHOT 207
19.14.2 PRODUCT PORTFOLIO 207
19.14.3 RECENT DEVELOPMENT 207
19.15 TEVA PHARMACEUTICAL INDUSTRIES LTD. 208
19.15.1 COMPANY SNAPSHOT 208
19.15.2 REVENUE ANALYSIS 208
19.15.3 PRODUCT PORTFOLIO 209
19.15.4 RECENT DEVELOPMENTS 209
19.16 TRB CHEMEDICA SA 210
19.16.1 COMPANY SNAPSHOT 210
19.16.2 PRODUCT PORTFOLIO 210
19.16.3 RECENT DEVELOPMENTS 211
19.17 VIATRIS INC. 212
19.17.1 COMPANY SNAPSHOT 212
19.17.2 REVENUE ANALYSIS 212
19.17.3 PRODUCT PORTFOLIO 213
19.17.4 RECENT DEVELOPMENTS 213
19.18 VIRCHOW BIOTECH 214
19.18.1 COMPANY SNAPSHOT 214
19.18.2 PRODUCT PORTFOLIO 214
19.18.3 RECENT DEVELOPMENT 214
19.19 ZUVENTUS HEALTHCARE LTD. (A SUBSIDIARY OF EMCURE PHARMACEUTICALS) 215
19.19.1 COMPANY SNAPSHOT 215
19.19.2 REVENUE ANALYSIS 215
19.19.3 PRODUCT PORTFOLIO 216
19.19.4 RECENT DEVELOPMENT 216
20 QUESTIONNAIRE 217
21 RELATED REPORTS 220
Call Us
( India toll free )
+91 835 605 0278
( US toll free )
+1 800 601 6071
Drop us an email at
sales@prudentmarkets.com
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
